Abstract

The extent of non-coding RNA alterations in patients with sepsis and their relationship to clinical characteristics, soluble mediators of the host response to infection, as well as an advocated in vivo model of acute systemic inflammation is unknown. Here, we obtained whole blood from 156 patients with sepsis and 82 healthy subjects among whom eight were challenged with lipopolysaccharide in a clinically controlled setting (human endotoxemia). Via next-generation microarray analysis of leukocyte RNA we found long non-coding RNA and, to a lesser extent small non-coding RNA, were significantly altered in sepsis relative to health. Long non-coding RNA expression, but not small non-coding RNA, were largely recapitulated in human endotoxemia. Integrating RNA profiles and plasma protein levels revealed known as well as previously unobserved pathways, including non-sensory olfactory receptor activity. We provide a benchmark dissection of the blood leukocyte 'regulome' that can facilitate prioritization of future functional studies.

Data availability

The datasets generated and analyzed in the current study are available in the Gene Expression Omnibus of the National Center for Biotechnology Information repository with primary data accession numbers GSE134364 (super-series), GSE134347 for patients and healthy volunteers (HTA 2.0 microarray), GSE134356 for the human endotoxemia model samples (HTA 2.0 microarray) and GSE134358 for all patients, healthy volunteers and human endotoxemia samples (miRNA-4.1 microarray).

Article and author information

Author details

  1. Brendon P Scicluna

    Center for Experimental Molecular Medicine, AMC, Amsterdam, Netherlands
    For correspondence
    b.scicluna@amc.uva.nl
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2826-0341
  2. Fabrice Uhel

    Center for Experimental Molecular Medicine, AMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4946-8184
  3. Lonneke A van Vught

    Center for Experimental Molecular Medicine, AMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  4. Maryse A Wiewel

    Center for Experimental Molecular Medicine, AMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  5. Arie J Hoogendijk

    Center for Experimental Molecular Medicine, AMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  6. Ingelore Baessman

    Cologne Center for Genomics, University of Cologne, Cologne, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Marek Franitza

    Cologne Center for Genomics, University of Cologne, Cologne, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Peter Nürnberg

    Cologne Center for Genomics, University of Cologne, Cologne, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Janneke Horn

    Intensive care medicine, AMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  10. Olaf L Cremer

    Intensive care medicine, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  11. Marc J Bonten

    Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  12. Marcus J Schultz

    Intensive care medicine, AMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  13. Tom van der Poll

    Infectious diseases, AMC, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  14. MARS consortium

Funding

Innovative Medicines Initiative (115523 | 115620 | 115737)

  • Marc J Bonten

Center for Translational Molecular Medicine (04I-201)

  • Tom van der Poll

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The institutional review boards of both participating centers approved an opt-out consent method (IRB No. 10-056C). The Dutch Central Committee on Research Involving Human Subjects and the Medical Ethics Committee of the Academic Medical Center, Amsterdam, the Netherlands, approved the study. Written informed consent was obtained from all healthy participants.

Copyright

© 2020, Scicluna et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,417
    views
  • 228
    downloads
  • 39
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Brendon P Scicluna
  2. Fabrice Uhel
  3. Lonneke A van Vught
  4. Maryse A Wiewel
  5. Arie J Hoogendijk
  6. Ingelore Baessman
  7. Marek Franitza
  8. Peter Nürnberg
  9. Janneke Horn
  10. Olaf L Cremer
  11. Marc J Bonten
  12. Marcus J Schultz
  13. Tom van der Poll
  14. MARS consortium
(2020)
The leukocyte non-coding RNA landscape in critically ill patients with sepsis
eLife 9:e58597.
https://doi.org/10.7554/eLife.58597

Share this article

https://doi.org/10.7554/eLife.58597

Further reading

    1. Immunology and Inflammation
    Josep Garnica, Patricia Sole ... Pere Santamaria
    Research Article

    Chronic antigenic stimulation can trigger the formation of interleukin 10 (IL-10)-producing T-regulatory type 1 (TR1) cells in vivo. We have recently shown that murine T-follicular helper (TFH) cells are precursors of TR1 cells and that the TFH-to-TR1 cell transdifferentiation process is characterized by the progressive loss and acquisition of opposing transcription factor gene expression programs that evolve through at least one transitional cell stage. Here, we use a broad range of bulk and single-cell transcriptional and epigenetic tools to investigate the epigenetic underpinnings of this process. At the single-cell level, the TFH-to-TR1 cell transition is accompanied by both, downregulation of TFH cell-specific gene expression due to loss of chromatin accessibility, and upregulation of TR1 cell-specific genes linked to chromatin regions that remain accessible throughout the transdifferentiation process, with minimal generation of new open chromatin regions. By interrogating the epigenetic status of accessible TR1 genes on purified TFH and conventional T-cells, we find that most of these genes, including Il10, are already poised for expression at the TFH cell stage. Whereas these genes are closed and hypermethylated in Tconv cells, they are accessible, hypomethylated, and enriched for H3K27ac-marked and hypomethylated active enhancers in TFH cells. These enhancers are enriched for binding sites for the TFH and TR1-associated transcription factors TOX-2, IRF4, and c-MAF. Together, these data suggest that the TR1 gene expression program is genetically imprinted at the TFH cell stage.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Stephanie Guillet, Tomi Lazarov ... Frédéric Geissmann
    Research Article

    Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.